Freyja Healthcare
Freyja Healthcare is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Freyja Healthcare.
Freyja Healthcare is a company.
Key people at Freyja Healthcare.
Freyja Healthcare is an early-stage medical device company founded in 2017, headquartered in Boston, MA, specializing in innovative surgical tools for women's health and beyond.[2][3] The company develops less invasive devices like the flagship VereSee™, a 2mm abdominal access video entry device with high-definition visualization for laparoscopic surgery, addressing gaps in safe, effective procedures for physicians and patients.[3][4] With $17M+ raised to date (including an $8M round in June 2024), four products in advanced development, 17 granted patents, and 21 pending, Freyja focuses on precision, control, and improved outcomes in minimally invasive gynecologic surgery.[2][3]
Serving surgeons and healthcare providers, Freyja solves longstanding challenges in women's health—such as blind entry risks and inefficient tools—through clinician-driven innovations that streamline procedures and elevate care standards.[1][2] Recent milestones include 510(k) clearance for VereSee™, signaling strong growth momentum toward commercialization in the expanding women's health market.[4]
Freyja Healthcare was founded in 2017 by Dr. Jon Ívar Einarsson, MD PhD MPH—a pioneering minimally invasive gynecologic surgeon, former Chief of MIGS at Brigham and Women's Hospital, retired Harvard OBGYN Professor, and past AAGL President—who identified critical needs for better surgical devices from his decades of teaching and operating.[2][3][5] Partnering with Jerry Brecher (CFO, serial medtech founder experienced in commercialization) and Dr. Gaby Moawad (renowned Ob-Gyn surgeon and George Washington University professor), the idea emerged from real-world surgeon frustrations with ineffective, invasive tools in women's health.[2]
Early traction built on this clinical insight: the team rapidly advanced a pipeline, secured funding, and achieved regulatory wins like VereSee™'s 510(k) clearance, while amassing 30+ granted patents amid a historically under-innovated field.[2][3][4] This clinician-entrepreneur blend propelled Freyja from concept to a robust portfolio targeting surgical efficiency.
Freyja rides the surge in women's health medtech, a market long neglected despite high unmet needs in minimally invasive gynecology, fueled by post-pandemic focus on efficient outpatient procedures and patient-centered care.[1][2] Timing aligns with laparoscopic advancements and regulatory tailwinds, as 510(k) clearances like VereSee™'s enable rapid market entry amid investor enthusiasm—evidenced by $17M+ funding from healthcare VCs.[3][4]
Market forces favor Freyja: aging populations drive surgical demand, while clinician shortages amplify needs for intuitive tools; the company's innovations influence ecosystems by setting new standards for visualization and access, potentially reshaping laparoscopy beyond Ob-Gyn.[2][4]
Freyja is poised for commercialization acceleration post-$8M raise, prioritizing VereSee™ launch, talent hires, and pipeline expansion into broader surgery.[3] Trends like AI-enhanced imaging and value-based care will amplify its precision tools, while women's health funding momentum sustains growth. Expect influence to grow via acquisitions (mirroring team exits like Hologic) or partnerships, solidifying Freyja as a leader in elevating surgical standards from its Boston base—transforming challenges into clinical excellence.[2][5]
Key people at Freyja Healthcare.
